COVID-19 Archive:臨床研究｜株式会社Smart119｜新型コロナウィルス感染症関連論文アーカイブ

Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone (Clinical Infectious Diseases 2021.8.22)

2021.09.02

Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce (NEJM 2021.9.1)

2021.08.31

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273(JAMA 2021.8.30)

2021.07.05

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 (Nature 2021.6.30)

2021.06.11

Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia (NEJM 2021.6.9)

2021.05.11

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers (JAMA 2021.5.6)

2021.05.10

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 (JAMA 2021.4.30)

2021.04.26

Acute Allergic Reactions to mRNA COVID-19 Vaccines (JAMA 2021.3.8)

2021.04.15

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination (NEJM 2021.4.9)

2021.04.15

SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women (JAMA 2021.4.12)

2021.04.12

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination (NEJM 2021.4.9)

2021.04.12

Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract (Nature 2021.4.6)

2021.04.06

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 (Nature 2021.3.15)

2021.03.16

Covid-19 Vaccine Resource Center(NEJM 2021.4.2)②

2021.03.16

Covid-19 Vaccine Resource Center （NEJM 2021.4.2)①

2021.03.15

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study (BMJ 2021.3.10)

2021.03.11

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study (Epub 2020.10.29)

2021.03.07

COVID-19 Archive: 臨床研究

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months (NEJM 2021.10.6)

Spontaneous Abortion Following COVID-19 Vaccination During Pregnancy (JAMA 2021.9.8)

Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone (Clinical Infectious Diseases 2021.8.22)

Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce (NEJM 2021.9.1)

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273(JAMA 2021.8.30)

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 (Nature 2021.6.30)

Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia (NEJM 2021.6.9)

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers (JAMA 2021.5.6)

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 (JAMA 2021.4.30)

Acute Allergic Reactions to mRNA COVID-19 Vaccines (JAMA 2021.3.8)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination (NEJM 2021.4.9)

SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women (JAMA 2021.4.12)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination (NEJM 2021.4.9)

Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract (Nature 2021.4.6)

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 (Nature 2021.3.15)

Covid-19 Vaccine Resource Center(NEJM 2021.4.2)②

Covid-19 Vaccine Resource Center （NEJM 2021.4.2)①

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study (BMJ 2021.3.10)

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study (Epub 2020.10.29)

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial (JAMA 2021.3.4)